Exploratory Study of the Cutaneous Penetration of Biodegradable Polymeric Microparticles in Atopic Dermatitis

NCT ID: NCT02369432

Last Updated: 2017-10-13

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-02-20
• Study Completion Date: 2017-10-03

Brief Summary

This proof of concept study aims to assess in patients suffering from atopic dermatitis if polymeric microparticles reach the pilosebaceous follicles of inflamed skin.

Detailed Description

Current treatments of inflammatory skin disorders such as acne, psoriasis or atopic dermatitis are primarily topical. They have the advantage of allowing the administration of active substances directly to the skin lesions.

However local treatments may have drawbacks (complex application, local and/or systemic side effects...) and cause poor compliance.

The use of drug carriers is viewed as one of the most promising strategies to target and control the release of active substances to various skin sites. Polymeric microparticles have shown to have a better stability and a more sustained release pattern than other types of drug vehicles such as liposomes.

Based on the results obtained in our preclinical experiments, this proof of concept study aims to assess, in patients suffering from atopic dermatitis, if biodegradable polymeric microparticles reach the pilosebaceous follicles of inflamed skin which would in turn serve as a reservoir of active substance.

Conditions

Atopic Dermatitis

Keywords

Drug carriers; Polymeric microparticles; Preferential accumulation in inflamed skin; Atopic dermatitis; Pilosebaceous follicles; Selective drug delivery; Drug reservoir

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Group of healthy volunteers and group of patients

• Healthy volunteers: Microparticles will be applied to the skin of the forearm and then a skin biopsy of this area will be performed
• Patients suffering from atopic dermatitis: Microparticles will be applied to the skin of the forearm both to an area affected by dermatitis and to an area deprived from the disease. A skin biopsy of these two areas will be performed

Group Type: EXPERIMENTAL

Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy

Intervention Type: DRUG

Interventions

Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy volunteers:

• Volunteers over 18
• Male volunteers under 65 or women of childbearing age (with a negative pregnancy test obtained at least 3 weeks before inclusion)
• Caucasian volunteers
• Volunteers having never shown any type of skin lesions regardless of its origin especially any allergic skin reactions.
• Volunteers having signed a free and informed consent form
• Volunteers affiliated to a social security system
• Patients:

• Patients over 18
• Male patients under 65 or women of childbearing age (with a negative pregnancy test obtained at least 3 weeks before inclusion)
• Caucasian patients
• Acute phase of atopic dermatitis with a SCORAD between 15 and 40
• Patients suffering from atopic dermatitis skin lesions ≥ 1.5 cm² on the inside of the forearm
• Patients having been treated by class II dermocorticoids with a two-week wash-out prior to inclusion
• Patients having signed a free and informed consent form
• Patients affiliated to a social security system

Exclusion Criteria

• Participants under 18
• Pregnant or Breastfeeding women
• Post-menopausal women
• Patients having skin lesions adjacent to the selected area
• Patients with complications of atopic dermatitis
• SCORAD <15 or >40
• Patients being treated with a topical or a systemic treatment influencing the skin penetration of the microparticles
• Patients allergics to any component of the formulation
• Patients using cosmetic products on their forearms
• Patients planning to expose themselves to the sun
• Patients with a known immune deficiency
• Patients allergic to any product or device used before, during or after the skin biopsy
• Patients suffering from known wound healing disorders
• Patients with known inherited ou acquired hemostasis disorders
• Patients unable to follow the protocol requirements
• Patients currently involved in another clinical trial (or whose participation has ended less than 2 weeks before inclusion)
• Patients who are not affiliated to a social security system
• Patients in an exclusion period following participation in another clinical trial
• Incapacitated adults
• Participants placed under tutorship or curatorship
• Participants under judicial protection

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University of Franche-Comté

OTHER

Sponsor Role: collaborator

Centre Hospitalier Universitaire de Besancon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Philippe HUMBERT

Role: PRINCIPAL_INVESTIGATOR

Centre Hospitalier Universitaire de Besancon

Locations

Regional University Hospital

Besançon, , France

Countries

France

Other Identifiers

API/2012/32

Identifier Type: -

Identifier Source: org_study_id